Introduction
============

Acute lung injury (ALI) often poses a great threat to human health ([@B2]; [@B22]). ALI is due to a large number of neutrophils into the lungs, and the release of a large number of pro-inflammatory mediators, resulting in damage to lung epithelial cells and endothelial cells ([@B24]). Although significant progress has been made in the pathophysiology and treatment of ALI, the mortality rate remains unchanged ([@B26]). Therefore, it is urgent to improve the effective treatment strategy for the patients. The onset of ALI, an early symptom of organ failure, is associated with lipopolysaccharide (LPS) or the elevated blood levels of endotoxin ([@B10]). Thus, LPS has been widely used to establish experimental model for drug development against ALI.

In recent years, lots of work have been carried out to elucidate the mechanisms of LPS-induced ALI. However, the good therapeutic approach remains controversial and uncertain. Accordingly, there is an urgent need to develop effective drugs to treat this disease. Dioscin (Dio, **Figure [1A](#F1){ref-type="fig"}**), a natural saponin from some medicinal herbs ([@B5]), has anti-inflammatory, anti-tumor and anti-hyperlipidaemic effects ([@B12]; [@B15]).

![**Dioscin inhibits proliferation of the cells treated with lipopolysaccharide (LPS) *in vitro.* (A)** The chemical structure of dioscin. **(B)** Effect of dioscin (75, 150, 300, 600, 1200, and 2400 ng/ml) on the viability of 16HBE cells for 24 h, and the effect of dioscin (150, 300, and 600 ng/ml) on the proliferation of 16HBE cells treated with LPS (100 ng/ml) for 6, 12, and 24 h. Values are expressed as the mean ± SEM (*n* = 5). \**p* \< 0.05 and \*\**p* \< 0.01 compared with model group. ^\#\#^*p* \< 0.01 compared with control group.](fphar-08-00120-g001){#F1}

In our previous study, we have reported that dioscin has significant effects on l LPS-induced liver injury ([@B33]), LPS-induced kidney injury ([@B19]), non-alcoholic fatty liver disease (NAFLD) ([@B32]), hepatic ischemia- reperfusion damage ([@B31]), and hepatic fibrosis ([@B36]). In our knowledge, dioscin has played significant roles on liver ([@B36]; [@B33]), kidney ([@B19]), bone ([@B29]), and brain ([@B30]). Nevertheless, the effects and mechanisms of dioscin against LPS-induced ALI rmains un-known.

The purpose of our work was to test the actions of dioscin on ALI caused by LPS and then to elucidate the possible mechanisms.

Materials and Methods {#s1}
=====================

Chemicals
---------

Dioscin was prepared from *Dioscorea nipponica* Makino in our laboratory with the purity over 98% analyzed by high-performance liquid chromatography ([@B35]; [@B8]). Dioscin was dissolved with 0.1% dimethylsulfoxide (DMSO) for *in vitro* experiments, or with 0.5% carboxymethylcellulose sodium (CMC-Na) solution for *in vivo* tests. CMC-Na, 4',6'-diamidino-2- phenylindole (DAPI), sodium dodecyl sulfate (SDS), and Tris were purchased from Sigma (St. Louis, MO, USA). A tissue protein extraction kit was obtained from Keygen Biotech. Co., Ltd. (Nanjing, China). A bicinchoninicacid (BCA) protein assay kit was purchased from the Beyotime Institute of Biotechnology (Jiangsu, China). MDA, SOD, NO, and iNOS assay kits were obtained from the Nanjing Jiancheng Institute of Biotechnology (Nanjing, China). RNAiso Plus, a PrimeScript^®^ RT Reagent Kit with gDNA Eraser (Perfect Real Time) and SYBR^®^ Premix Ex Taq^TM^ II (Tli RNase H Plus) were purchased from TaKaRa Biotechnology Co., Ltd. (Dalian, China).

Cell Culture
------------

The human bronchial epithelial (16HBE) cells were obtained from American type culture collection (ATCC) (Manassas, VA, USA) and maintaind in RPMI medium 1640 (Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) in humidified atmosphere containing 5% CO~2~ and 95% O~2~ at 37°C.

Dioscin Toxicity Assay
----------------------

The 16HBE cells were seeded into 96-well plates at a density of 5 × 10^4^ cells/ml per well for 24 h before treatment, and then incubated for another 24 h in the presence of different concentrations of dioscin (75, 150, 300, 600, 1200, and 2400 ng/ml). The cell proliferation was measured using the MTT method.

Cell Proliferation Assay
------------------------

The 16HBE cells were plated into 96-well plates at a density of 5 × 10^4^ cells/ml for 24 h and then incubated for 6, 12, and 24 h in the presence of various concentrations of dioscin (150, 300, and 600 ng/ml) caused by LPS (100 ng/ml). The cells were measured according to the MTT method.

Detection of Intracellular ROS Level
------------------------------------

The 16HBE cells were plated in 6-well plates at a density of 5 × 10^4^ cells/ml and treated with dioscin at the concentrations of 150, 300 and 600 ng/ml for 24 h, then exposed to LPS for 24 h. The cells were harvested and re-suspended in 1 ml dichloro -dihydrofluorescein diacetate (DCFH-DA) (10 μM) for the detection of ROS level, which was imaged by fluorescence microscope (Olympus, Tokyo, Japan).

LPS-Induced ALI *In vivo*
-------------------------

Male C57BL/6J mice weighing 18--22 g and male Wistar rats weighing 180--220 g were obtained from the Experimental Animal Centre of Dalian Medical University, Dalian, China (SCXK (Liao): 2013--0003). All experiments were approved by the Animal Care and Use Committee of Dalian Medical University, and the experimental procedures were performed in strict accordance with Legislation Regarding the Use and Care of Laboratory Animals of China. Before the experiments, the animals were allowed to suit the new environment for 7 days, and housed in a room under 12 h light/dark cycle, a controlled temperature at 23 ± 2°C and a relative humidity at 60 ± 10%. The mice and rats were randomly divided into five groups (*n* = 8 per group): control, model (LPS-treated) and dioscin-treated groups, respectively. The animals were oral administered with dioscin for 7 consecutive days at the doses of 80, 40, and 20 mg/kg for mice, and 60, 30, and 15 mg/kg for rats. Lung injury in mice and rats were induced by intraperitoneal (i.p.) LPS at the doses of 8 mg/kg and 5 mg/kg 2 h before the last administration. After 7 days, the animals were sacrificed after an overnight fast. Then, blood and lung tissue were collected and stored for further analysis.

Histological Assay
------------------

The lung tissues were fixed in 10% formalin, embedded in paraffin, and sectioned into Five-micron-thick slices. The slices were then stained with haematoxylin-eosin (H&E). Images were captured using a light microscopy (Nikon Eclipse TE2000-U, Nikon, Japan) at 200× magnification, and the degree of lung injury was quantified using Image-Pro Plus 6.0 software.

Antioxidant Assay *In vivo*
---------------------------

The levels of MDA, SOD, NO, and iNOS in lung tissues were detected using commercial kits according to the manufacturer's instructions.

Immunofluorescence Assay
------------------------

For the immunofluorescence staining of TLR4 and MyD88, the tissue slices or formal in-fixed cells were preformed using primary antibodies (Santa Cruz, California, USA) in a humidified chamber at 4°C overnight. After washing twice in PBS, the tissue slices or the cells were incubated with a fluorescein-labeled secondary antibody for 1 h. Eventually, cell nuclei were stained with DAPI (5 μg/ml). The immunostained images were captured using a fluorescence microscope (Olympus, Tokyo, Japan).

Quantitative Real-Time PCR Assay
--------------------------------

Total RNA samples from lung tissues were extracted using RNAiso Plus reagent following the manufacturer's protocol. Reverse transcription for cDNA synthesis and quantitative real-time PCR were performed as previously described. The forward (F) and reverse (R) primers for the tested genes are provided in **Table [1](#T1){ref-type="table"}**. A no-template control was analyzed in parallel for each gene, and a GAPDH gene was selected as the housekeeping gene in our study. Eventually, the unknown template was calculated through the standard curve for quantitative analysis.

###### 

The primer sequences used for real-time PCR assay in the present work.

  Gene          GenBank accession   Forward primer (5'--3')     Reverse primer (5'--3')
  ------------- ------------------- --------------------------- ---------------------------
  Mouse GAPDH   NM_008084.2         TGTGTCCGTCGTGGATCTGA        TTGCTGTTGAAGTCGCAGGAG
  Mouse TNF-α   NM_013693.2         TATGGCCCAGACCCTCACA         GGAGTAGACAAGGTACAACCCATC
  Mouse IL-1β   NM_008361.3         TCCAGGATGAGGACATGAGCAC      GAACGTCACACACCAGCAGGTTA
  Mouse IL-6    NM_031168.1         CCACTTCACAAGTCGGAGGCTTA     CCAGTTTGGTAGCATCCATCATTTC
  Rat GAPDH     NM_017008.3         GGCACAGTCAAGGCTGAGAATG      ATGGTGGTGAAGACGCCAGTA
  Mouse IL-1β   NM_031512.2         CCCTGAACTCAACTGTGAAATAGCA   CCCAAGTCAAGGGCTTGGAA
  Rat IL-6      NM_012589.1         ATTGTATGAACAGCGATGATGCAC    CCAGGTAGAAACGGAACTCCAGA
  Rat TNF-α     NM_012675.3         TCAGTTCCATGGCCCAGAC         GTTGTCTTTGAGATCCATGCCATT
  Human GAPDH   NM_002046.3         GCACCGTCAAGGCTGAGAAC        TGGTGAAGACGCCAGTGGA
  Mouse IL-1β   NM_000576.2         CTGAGCACCTTCTTTCCCTTCA      TGGACCAGACATCACCAAGCT
  Human IL-6    NM_000600.3         TGGCTGAAAAAGATGGATGCT       TCTGCACAGCTCTGGCTTGT
  Human TNF-α   NM_000594.3         TGTAGCCCATGTTGTAGCAAACC     GAGGACCTGGGAGTAGATGAGGTA

Western Blotting Assay
----------------------

The protein samples from the cells and lung tissues were isolated using the protein extraction kit (Beyotime Biotechnology, Haimen, China), and the protein content was determined using a BCA Protein Assay Kit. The protein samples were loaded on to the SDS-PAGE gel (8--15%), separated electrophoretically, and transferred on to a PVDF membrane (Millipore, USA). After blocking nonspecific binding sites for 1 h with 5 % dried skim milk in TTBS at 37°C, the membrane was individually incubated for overnight at 4°C with the primary antibodies listed in **Table [2](#T2){ref-type="table"}**. Then the membrane was incubated at room temperature for 2 h with horseradish peroxidase-conjugated antibodies at a 1:2000 dilution. Protein expression was detected by the enhanced chemiluminescence (ECL) method. Protein bands were imaged using a Bio-Spectrum Gel Imaging System (UVP, Upland, CA, USA) and normalized with GAPDH as an internal control (IOD of objective protein versus IOD of GAPDH protein).

###### 

The information of the antibodies used in the present work.

  Antibody   Source   Dilutions   Company
  ---------- -------- ----------- -------------------------------------
  GAPDH      Rabbit   1:2000      Proteintech Group, Chicago, IL, USA
  TLR4       Rabbit   1:1000      Santa Cruz, CA, USA
  MyD88      Mouse    1:1000      Santa Cruz, CA, USA
  TRAF6      Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  TKB1       Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  TRAF3      Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  p-PI3K     Rabbit   1:1000      Santa Cruz, CA, USA
  PI3K       Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  p-Akt      Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  Akt        Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  p-IκBα     Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  IκBα       Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  p-NF-κB    Rabbit   1:1000      Proteintech Group, Chicago, IL, USA
  NF-κB      Rabbit   1:1000      Proteintech Group, Chicago, IL, USA

TLR4 Gene Transfection in Cells
-------------------------------

Overexpressed DNA transfection was used to upregulate TLR4 expression levels. The 16HBE cells were transfected with pPICZA-TLR4 plasmid DNA using Lipofectamine Plus Reagent (Invitrogen Life Technologies, CA, USA) according to the manufacturer's instructions. Twenty-four hours after transfection, the cells were subjected to serum deprivation for 24 h before treated by LPS (100 ng/ml) in the presence or absence of dioscin (600 ng/ml) for an additional 24 h. Then, the level of ROS, and the protein levels of TLR4, MyD88, TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF-κB were determined.

Statistical Analysis
--------------------

Data were presented as the mean ± standard error of the mean (mean ± SEM). One-way ANOVA or two tailed student's *t*-test was used where appropriate. Statistical significance was set at *p* \< 0.05 or *p* \< 0.01.

Results
=======

Dioscin Inhibits Proliferation of the Cells Treated with LPS *In vitro*
-----------------------------------------------------------------------

As shown in **Figure [1B](#F1){ref-type="fig"}**, dioscin at the concentrations of 75, 150, 300, and 600 ng/ml for 16HBE cells under 24 h treatment showed no statistically significant difference in cell viability. Compared with LPS group, dioscin at the concentrations of 150, 300, and 600 ng/ml under 6, 12, and 24 h treatment significantly changed cell viability. Under these conditions, dioscin effectively inhibited cell proliferation treated by LPS with time- and dose- dependent manners.

Dioscin Rehabilitates LPS-Induced ALI
-------------------------------------

As shown in **Figure [2A](#F2){ref-type="fig"}**, dioscin at the concentrations of 150, 300, and 600 ng/ml under 24 h treatment was selected to protect LPS-induced ALI *in vitro*. As shown in **Figure [2B](#F2){ref-type="fig"}**, with the challenge of LPS, lung tissues were significantly damaged with the histopathologic changes including interstitial edema and hemorrhage, alveolar wall thickening, and notable infiltration of neutrophils and macrophages in the lung parenchyma and alveolar spaces. However, these symptoms were markedly reversed by dioscin.

![**Dioscin rehabilitates LPS-induced injury *in vitro* and *in vivo*. (A)** Effect of dioscin (150, 300, and 600 ng/ml for 24 h pretreatment) on the cellular morphology and structure of 16HBE by bright image (200 × magnification) investigation. **(B)** Effects of dioscin on LPS-induced lung injury in mice and rats based on H&E staining (200 × original magnification).](fphar-08-00120-g002){#F2}

Dioscin Attenuates Oxidative Stress *In vitro* and *In vivo*
------------------------------------------------------------

As shown in **Figure [3A](#F3){ref-type="fig"}**, compared with model group, dioscin markedly decreased ROS level in 16HBE cells. As shown in **Figure [3B](#F3){ref-type="fig"}**, the levels of MDA, SOD, NO, and iNOS in mice and rats were significantly reversed by dioscin compared with model groups.

![**Dioscin attenuates oxidative stress *in vitro* and *in vivo.* (A)** Effect of dioscin (150, 300, and 600 ng/ml for 24 h pretreatment) on the ROS level in 16HBE cells by immunofluorescence assay (200 × magnification). **(B)** Effect of dioscin on the levels of MDA, SOD, NO, and iNOS in mice and rats. Values are expressed as the mean ± SEM (*n* = 8). ^\#\#^*p* \< 0.01 compared with control group; \**p* \< 0.05 and \*\**p* \< 0.01 compared with model group.](fphar-08-00120-g003){#F3}

Dioscin Adjusts TLR4/MyD88 Signal *In vitro*
--------------------------------------------

As shown in **Figures [4A,B](#F4){ref-type="fig"}**, compared with model group, the protein levels of TLR4 and MyD88 in 16HBE cells were significantly down-regulated by dioscin in a dose-dependent manner based on western blotting and immunofluorescence assays. As shown in **Figure [4C](#F4){ref-type="fig"}**, the expression levels of TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF-κB in model group were markedly increased compared with normal group, which were all significantly down-regulated by dioscin in 16HBE cells. The mRNA levels of IL-1β, IL-6 and TNF-α were also significantly decreased by dioscin *in vitro* (**Figure [4D](#F4){ref-type="fig"}**).

![**Dioscin adjusts TLR4/MyD88 signal *in vitro*. (A)** Effect of dioscin on the protein levels of TLR4 and MyD88 in 16HBE cells. **(B)** Effect of dioscin on the expression levels of TLR4 and MyD88 in 16HBE cells based on immunofluorescence assay (400 × original magnification). **(C)** Effect of dioscin on the expression levels of TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF-κB in 16HBE cells. **(D)** Effect of dioscin on the mRNA levels of TNF-α, IL-1β, and IL-6 in 16HBE cells. Values are expressed as the mean ± SEM (*n* = 3). ^\#\#^*p* \< 0.01 compared with control group; \*\**p* \< 0.01 compared with model group.](fphar-08-00120-g004){#F4}

Dioscin Adjusts TLR4/MyD88 Signal *In vivo*
-------------------------------------------

As shown in **Figures [5A,B](#F5){ref-type="fig"}**, compared with model groups, the protein levels of TLR4 and MyD88 in mice and rats were significantly down-regulated by dioscin in a dose-dependent manner based on western blotting and immunofluorescence assays. As shown in **Figure [5C](#F5){ref-type="fig"}**, the expression levels of TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF-κB in model groups were markedly increased compared with normal groups, which were all significantly down-regulated by dioscin in mice and rats. The mRNA levels of IL-1β, IL-6, and TNF-α were also significantly decreased by dioscin (**Figure [5D](#F5){ref-type="fig"}**).

![**Dioscin adjusts TLR4/MyD88 signal *in vivo.* (A)** Effect of dioscin on the protein levels of TLR4 and MyD88 in mice and rats. **(B)** Effect of dioscin on the expression levels of TLR4 and MyD88 based on immunofluorescence assay in mice and rats (200 × original magnification). **(C)** Effect of dioscin on the expression levels of TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF-κB in mice and rats. **(D)** Effect of dioscin on the mRNA levels of TNF-α, IL-1β, and IL-6 in mice and rats. Values are expressed as the mean ± SEM (*n* = 3). ^\#\#^*p* \< 0.01 compared with control group; \**p* \< 0.05 and \*\**p* \< 0.01 compared with model group.](fphar-08-00120-g005){#F5}

TLR4 DNA Abrogates the Protective Effect of Dioscin
---------------------------------------------------

As shown in **Figures [6A,B](#F6){ref-type="fig"}**, dioscin markedly suppressed ROS level, and the protein levels of TLR4 and MyD88 in cells were also decreased by the compound based on immunofluorescence assay. Compared with LPS group, the over-expressed level of TLR4 was down-regulated by dioscin after transfection. In addition, the protein levels of TLR4, MyD88, TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF-κB were markedly decreased by dioscin after transfection (**Figure [6C](#F6){ref-type="fig"}**).

![**TLR4 DNA abrogates the protective effect of dioscin. (A,B)** Effect of dioscin on the level of ROS, and the expression levels of TLR4 and MyD88 based on immunofluorescence assay (400 × original magnification). **(C)** Effect of dioscin on the protein levels of TLR4, MyD88, TRAF6, TKB1, TRAF3, p-PI3K, p-Akt, p-IκBα, and p-NF- κB in 16HBE cells after transfection.](fphar-08-00120-g006){#F6}

Discussion
==========

Acute lung injury is a direct and indirect damage caused by diffuse pulmonary interstitial and alveolar edema, and acute hypoxic respiration ([@B17]; [@B25]). LPS, one ligand of TLR4 receptor, can induce the production of inflammatory cytokines and cause lung injury ([@B23]). There are evidences that TLR4 mediates microbial infection of immune and inflammatory responses and is involved in the pathogenesis of LPS-induced ALI ([@B3]; [@B11]). The TLR4 signaling pathway is involved in MyD88 dependent and non-dependent pathways, and the development of LPS-caused ALI may be one potent mediator to activate inflammation ([@B28]). The TLR4 signaling pathway includes a variety of downstream genes. Endogenous PI3K/Akt signaling pathway is one of the important downstream pathway, which can regulate the negative feedback of LPS stimulation ([@B4]). LPS activates TLR4/MyD88-dependent signaling pathways, leading to the phosphorylation of PI3K and Akt, which subsequently leads to nuclear translocation of NF-κB ([@B20]). NF-κB can regulate the levels of inflammatory cytokines including TNF-α, IL-6, and IL-1β ([@B6]).

Although inflammation is common in almost all patients with lung injury, the molecular link between inflammation and progression of lung injury and pneumonia remains unclear. Studies have shown that excessive release of ROS may lead to over activation of innate immune cells, overproduction of cytokines, and even the damage of the end organ in the process of LPS induced shock ([@B7]; [@B14]). TLR4 signal enhances ROS level, followed by the increased levels of MDA, iNOS, NO, and the reduced SOD level. High levels of SOD can protect ALI ([@B13]), and over-production of free radicals can increase MDA level ([@B18]). In the course of the development of ALI induced by LPS, the activation of pulmonary macrophages and inflammatory cell infiltration are the basic events of lung parenchyma damage ([@B1]; [@B21]). The excessive inflammatory response further leads to vascular injury and diffuse alveolar damage, which can aggravate lung injury and acute respiratory distress syndrome ([@B16]). For these reasons, these inflammatory mediators play a key role in ALI, and low levels of them may reduce LPS-induced ALI. As the main feature of inflammation in ALI, increased levels of inflammatory mediators can aggravate lung injury ([@B34]). More importantly, LPS through TLR4 signal can produce proinflammatory cytokines to promote LPS-induced ALI ([@B9]; [@B27]).

Dioscin has potent effects against LPS-induced liver and kidney injury in our previous studies ([@B19]; [@B33]). In our work, dioscin markedly protected LPS-induced 16HBE cell injury, and obviously alleviated the histopatholo- gical changes in mice and rats, suggesting that dioscin showed good action against ALI caused by LPS. We found that dioscin markedly suppressed the ROS level in 16HBE cells. In addition, PLS-caused high levels of MDA, NO, iNOS, and low level of SOD in mice and rats were all inhibited by dioscin, indicating that the anti-oxidant activity of the natural product may be one potential mechanism against LPS-induced ALI. What's more, dioscin markedly decreased TNF-α, IL-1β, and IL-6 levels in mice and rats, suggesting that the anti-inflammatory effect of the natural product may be one potential mechanism against LPS-induced ALI. The mechanism results showed the action of dioscin on LPS-induced ALI may be via adjusting TLR4/MyD88 signal pathway.

Conclusion
==========

Our results demonstrated that dioscin conferred direct protective effects on LPS- induced ALI by inhibitiing oxidative stress and inflammation responses, which also provide new insights on the mechanisms of dioscin to treat ALI.

Author Contributions
====================

HY was responsible for the planning, execution of all experiments and preparation of the manuscript. YS, SS, YQ, and XT were responsible for LPS-induced acute lung injury model experiments. LX, LY, XH, and YX were responsible for the preparation, isolation and bioavailability study of dioscin. HL, HS, and JP provided critical inputs for the experiments. JP was responsible for the conceptualization, planning, execution and troubleshooting of the experiments, preparation of the manuscript and the financial support.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was financially supported by the Project of Liaoning BaiQianWan Talents Program (2015-65).

Akt

:   protein kinase B

iNOS

:   inducible nitric oxide synthase

IκBα

:   inhibitor of nuclear factor κB alpha

IL-1

:   interleukin-1
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:   interleukin-6
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:   malondialdehyde

MyD88

:   myeloid differentiation factor 88

NF-κB

:   nuclear factor κB
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:   nitric oxide

PI3K

:   phosphoinositide 3-kinase

SOD

:   superoxide dismutase

TKB1

:   TANK-binding kinase 1

TLR4

:   toll-like receptor 4

TNF-α

:   tumour necrosis factor-α

TRAF3

:   TNF receptor-associated factor 3

TRAF6

:   tumor necrosis factor receptor-associated factor 6.
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